210 related articles for article (PubMed ID: 12453646)
21. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.
Kreiger PA; Okada Y; Simon S; Rorke LB; Louis DN; Golden JA
Acta Neuropathol; 2005 Apr; 109(4):387-92. PubMed ID: 15739101
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
[TBL] [Abstract][Full Text] [Related]
23. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors.
Kuo LT; Kuo KT; Lee MJ; Wei CC; Scaravilli F; Tsai JC; Tseng HM; Kuo MF; Tu YK
Int J Cancer; 2009 Jun; 124(12):2872-9. PubMed ID: 19330828
[TBL] [Abstract][Full Text] [Related]
24. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
25. Oligodendrogliomas: impact of molecular genetics on treatment.
Hartmann C; von Deimling A
Neurol India; 2005 Jun; 53(2):140-8. PubMed ID: 16010049
[TBL] [Abstract][Full Text] [Related]
26. Current diagnosis and treatment of oligodendroglioma.
Engelhard HH
Neurosurg Focus; 2002 Feb; 12(2):E2. PubMed ID: 16212319
[TBL] [Abstract][Full Text] [Related]
27. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
[TBL] [Abstract][Full Text] [Related]
28. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
[TBL] [Abstract][Full Text] [Related]
29. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
30. [Significance and prospects of study on molecular alterations in oligodendrogliomas].
Gresner SM; Liberski PP
Neurol Neurochir Pol; 2007; 41(4):333-9. PubMed ID: 17874342
[TBL] [Abstract][Full Text] [Related]
31. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
32. [The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].
Kros JM
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1379-85. PubMed ID: 15997690
[TBL] [Abstract][Full Text] [Related]
33. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
34. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
[TBL] [Abstract][Full Text] [Related]
35. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
Kanner AA; Staugaitis SM; Castilla EA; Chernova O; Prayson RA; Vogelbaum MA; Stevens G; Peereboom D; Suh J; Lee SY; Tubbs RR; Barnett GH
J Neurosurg; 2006 Apr; 104(4):542-50. PubMed ID: 16619658
[TBL] [Abstract][Full Text] [Related]
36. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
Deininger MH; Weller M; Streffer J; Meyermann R
Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathology of oligodendroglial tumors.
Hartmann C; von Deimling A
Recent Results Cancer Res; 2009; 171():25-49. PubMed ID: 19322536
[TBL] [Abstract][Full Text] [Related]
38. Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma.
Mut M; Güler-Tezel G; Lopes MB; Bilginer B; Ziyal I; Ozcan OE
Clin Neuropathol; 2005; 24(5):225-9. PubMed ID: 16167546
[TBL] [Abstract][Full Text] [Related]
39. Morphologic and molecular genetic aspects of oligodendroglial neoplasms.
Bigner SH; Rasheed BK; Wiltshire R; McLendon RE
Neuro Oncol; 1999 Jan; 1(1):52-60. PubMed ID: 11550302
[TBL] [Abstract][Full Text] [Related]
40. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.
Zlatescu MC; TehraniYazdi A; Sasaki H; Megyesi JF; Betensky RA; Louis DN; Cairncross JG
Cancer Res; 2001 Sep; 61(18):6713-5. PubMed ID: 11559541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]